Johnson & Johnson (JNJ)
J&J's Pipeline Surge Sets Up Stronger Growth From New Drugs in 2026
JNJ's rapid pipeline progress and new drug approvals in 2025 set the stage for stronger growth impact from its expanding portfolio in 2026.
Johnson & Johnson: Deserves A Place In Conservative Dividend Growth Portfolios
Johnson & Johnson demonstrates a robust historical dividend growth profile, highlighted by 63 years of consecutive hikes. JNJ has an AAA credit rating, adding safety for the dividend. Though there are clear risks, the solid fundamentals of this company and the decent growth prospects make it an attractive investment compared to the highly valued overall market.
Johnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth Knowing
Johnson & Johnson (JNJ) closed the most recent trading day at $239.93, moving +1.98% from the previous trading session.
J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?
JNJ stock holds strong above key SMAs for 8 months as Innovative Medicine strength, new drugs and MedTech gains fuel momentum despite patent and legal risks.
Brokers Suggest Investing in Johnson & Johnson (JNJ): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
J&J Expands New Drug Portfolio With Icotyde's FDA Approval
J&J wins FDA nod for Icotyde, a once-daily oral psoriasis pill, boosting its new drugs portfolio and challenging injectable treatments in a key market.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company
Question: What caused JNJ stock to rise 70% since early 2025?
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Johnson & Johnson said the FDA has approved its once-daily psoriasis pill Icotyde. Icotyde targets IL-23, rivaling best-selling shots Tremfya and Skyrizi.
J&J or Merck? Key Factors Investors Must Weigh Right Now
Johnson & Johnson JNJ and Merck MRK are among the top U.S. healthcare giants, making them ideal candidates for a direct comparison.
US FDA approves J&J's oral psoriasis pill
The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for psoriasis, the company said on Wednesday, paving the way for a more convenient treatment option for patients with the chronic autoimmune condition that causes itchy, scaly, and inflamed patches of skin.
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
Johnson & Johnson (JNJ) reached $238.11 at the closing of the latest trading day, reflecting a -2.09% change compared to its last close.
